OPTIMI HEALTH CORP - OPTHF STOCK NEWS

Optimi Health Corp. (OTCQX: OPTHF) has entered a large-scale international distribution agreement with Avida Global, a UK-based wellness products producer. Optimi will supply Avida with its functional mushroom supplement formulations, making Avida the exclusive distributor in several countries including the UK, EU, and Japan. The functional mushroom market in Europe is projected to reach USD 107 million by 2028. This partnership aims to leverage Avida's distribution network while aligning with Optimi’s goal to become a top supplier in the industry and exploring future sales of psilocybin mushrooms.

Optimi Health Corp. (CSE: OPTI, OTCQX: OPTHF) announced an operational update regarding its year of commercialization plan initiated in Q1 2022. The company focuses on producing EU-GMP grade psilocybin and synthetic psychedelics. Recent advancements in regulatory support are noted, with FDA approval for psychedelic therapy anticipated within 24 months. Optimi has secured multiple supply agreements and is positioned to launch its product catalogue, including Canada’s first therapeutic psilocybin product, Blue Serenity. The company is on track to begin large-scale MDMA production by October 2022.

Optimi Health Corp. has entered its first international psilocybin supply agreement with Promises Innovative Recovery in Costa Rica. This partnership aims to establish a Center of Excellence for psychedelic-assisted mental health treatments, backed by Costa Rican regulatory advancements. CEO Bill Ciprick highlighted the importance of a consistent psilocybin supply for research and patient care. The company also appointed Justin Kirkland to their Medical & Clinical Advisory Board to enhance treatment protocols. This strategic move positions Optimi favorably in the growing psychedelic therapy market.

Optimi Health Corp. announced three new distribution agreements for its Optimi Life nutraceutical mushroom products with Well.ca, Vitasave, and Healthy Planet. These deals enhance the company's B2B distribution network and are expected to facilitate its expansion into international markets. The agreements come shortly after the successful February launch of Optimi Life, which aims to meet the growing consumer demand for high-quality mushroom products. CEO Bill Ciprick highlighted the anticipated growth in the functional mushroom market, projected to expand by 9.5% annually over the next six years.

Optimi Health Corp. has received permission from Health Canada to manufacture and distribute MDMA and additional psychedelics, enhancing its position as a global leader in this sector. The company plans to begin production of MDMA in October 2022 at its EU-GMP approved facility. This amendment supports Optimi's commercialization strategy, with CEO Bill Ciprick emphasizing operational transparency and regulatory compliance. Optimi also aims to address growing market needs amidst evolving regulatory landscapes in Canada and the U.S., with increasing interest from clinical trial researchers and drug developers.

Optimi Health Corp. (OTCQX: OPTHF) has launched Blue Serenity, Canada's first natural psilocybin product, in collaboration with psilocybin advocate Thomas Hartle. This product contains 25 mg of psilocybin derived from Panaeolus cyanescens mushrooms, aiming to assist patients under Canada's Special Access Program. Proceeds will benefit psilocybin therapy access for underserved adults through Hartle's new charity. The company will also donate $5,000 to this initiative. The launch reflects Optimi's commitment to compassionate care and expanding access to psychedelic therapies.

Optimi Health Corp. has secured a supply agreement with Bloom Psychedelic Therapy And Research Centre to provide natural psilocybin for clinical trials aimed at enhancing mental health. This partnership is positioned to establish Canada as a leader in psychedelics, leveraging Optimi's GMP-grade psilocybin and Bloom's therapeutic expertise. The initial phase I study will explore the optimal low doses of psilocybin for improving overall well-being without hallucinogenic effects. This follows Optimi's development of a state-of-the-art 20,000 sq ft facility for psilocybin production in British Columbia.

Optimi Health Corp (CSE: OPTI, OTCQX: OPTHF) has entered a supply agreement with Calgary-based SABI Mind for the provision of GMP psilocybin and MDMA. This agreement enables SABI's clinical staff to utilize these substances in psychedelic-assisted therapies pending licensing approval from Health Canada. The collaboration marks a significant milestone in Canada’s psychedelics sector, aiming to address mental health conditions like PTSD and depression. Optimi is also pursuing an amendment to its Controlled Substance Dealer’s Licence to enhance its capabilities in synthetic MDMA production.

Optimi Health Corp has submitted a request to Health Canada for an amendment to its Controlled Substances Dealer’s Licence to synthesize and distribute pharmaceutical-grade MDMA at its facility in Princeton, British Columbia. This move is part of the company’s strategy to commercialize synthetic psychedelics, capitalizing on growing demand in research, especially from Phase III MDMA studies led by MAPS. Optimi aims to expand its offerings and improve revenue generation through standardized drug testing and clinical trials.